America is facing one of the worst influenza seasons in recent history. The influenza virus is one of the top ten causes of death in elderly people. Longeveron is conducting a multi-center, randomized, placebo controlled trial using its Longeveron Mesenchymal Stem Cells (LMSCs) to measure the safety of treatment with LMSCs to improve vaccine response in patients with Aging Frailty.
Longeveron has completed enrollment of its second cohort for this trial and intends to complete enrollment for the trial the influenza season. The Company is ahead of schedule on enrollment for this important trial and expects data in 2018.
